Hepatocellular Carcinoma

The combination of atezolizumab and bevacizumab prolonged survival compared with standard-of-care sorafenib for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy, according to topline data from the phase 3 IMbrave150 study.

CHICAGO — Researchers determined clinical scores that assessed short-term risks for liver disease associated with isolated heart transplantation with the Fontan procedure in pediatric patients, according to a study presented at NASPGHAN 2019.

Recent study data showed disparities in hepatitis B virus infection rates between ethnic groups as well as among between U.S.-born and foreign-born patients.

Patients who developed hepatitis C-related hepatocellular carcinoma after achieving sustained virologic response with interferon-free direct-acting antivirals had a 60% to 70% improvement in 5-year survival compared with untreated patients.

In contrast to previous study results, hepatocellular carcinoma and decompensated cirrhosis rates were similar between patients coinfected with hepatitis C and HIV and those with hepatitis C alone, according to data.

As liver cancer rates continue to increase globally, researchers have focused on novel treatment options including combination therapies and second-line options for patients with insufficient response to initial therapy.

AVEO Oncology initiated enrollment in an early trial of a combination therapy using Fotivda and Imfinzi for the treatment of hepatocellular carcinoma with no prior systemic therapy, according to a press release.

Investigators have completed trial enrollment for two novel compositions of endogenous metabolic modulators under evaluation as interventions to address dysregulated metabolism in patients with nonalcoholic fatty liver disease, according to a press release from Axcella.

Dual-photon microscopy automated quantification of fibrosis-related parameters provided accurate assessments of fibrosis in patients with nonalcoholic fatty liver disease, according to data published in Gut.

Statin therapy correlated with a reduced risk for hepatocellular carcinoma in patients with chronic hepatitis B, according to results published in Hepatology.